Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US2546041011
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00W9MJK79
IRON
Disc Medicine Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Disc Medicine Inc
ISIN
US2546041011
TICKER
IRON
MIC
XNAS
REUTERS
IRON.OQ
BLOOMBERG
IRON US
Sat, 20.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.06.2026       Disc Medicine
US2546041011

NEW YORK, June 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materiall...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inves...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Sun, 14.06.2026       Disc Medicine
US2546041011

NEW YORK, June 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materiall...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announces updated data from multiple clinical programs to be presented at...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has completed a Type A meeting with the US Food and Drug Adm...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       Disc Medicine
US2546041011

NEW YORK, June 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 05.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Disc Medicine
US2546041011

NEW YORK, June 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - June 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin f...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Sat, 30.05.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Disc Medicine
US2546041011

NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegat...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.05.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 18.05.2026       Disc Medicine
US2546041011

NEW YORK, May 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegat...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing p...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematolo...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Disc Medicine
US2546041011

NEW YORK, May 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegat...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at tw...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Disc Medicine
US2546041011

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       Disc Medicine
US2546041011

NEW YORK, May 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegati...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing pu...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2026, and...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing pu...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Disc Medicine
US2546041011

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Disc Medicine
US2546041011

NEW YORK, April 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alleg...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine, Inc. may have issued materially misleading business information to th...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       Disc Medicine
US2546041011

NEW YORK, April 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alleg...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of D...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Disc Medicine
US2546041011

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Disc Medicine
US2546041011

NEW YORK, April 14, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alle...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Disc Medicine
US2546041011

NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allega...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Disc Medicine
US2546041011

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) ("Disc Medicine, Inc.") concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Respons...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Disc Medicine
US2546041011

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Disc Medicine
US2546041011

Investigation examines gap between reported figures and GAAP results at Disc Medicine ahead of its 21.9% stock collapse NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating whether Disc Medicine, Inc. (NASDAQ: IRON) and certain of its officers fulfilled their disclosure obligations to investors in the period leading...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Disc Medicine
US2546041011

NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alleg...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink